Form 4 for KPTI Karyopharm Therapeutics Inc.
Accepted 2024-01-25 00:00:00 ET · period of report 2024-01-24 · accession 0000950170-24-007588 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-01-25 | 2024-01-24 | KPTI | Mason Michael | EVP, CFO, Treas | A - Grant | $0.00 | +13.3K | 251.2K | +6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-24 | A | A | 13,333 | $0.00 | 251,150 | D | — | — | (F1) Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of a certain clinical milestone, as certified by the issuer's compensation committee on January 24, 2024. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs will vest on February 28, 2024, the first anniversary of the grant date, subject to continued employment through such vesting date. |